Why Isis Pharmaceuticals Inc. Shares Roared Higher

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Isis Pharmaceuticals (NASDAQ: ISIS  ) , a biopharmaceutical company developing a wide array of therapies using its antisense drug discovery platform, spiked higher by as much as 13% after reporting positive mid-stage data on ISIS-FXI in the prevention of venous thrombosis in patients undergoing total knee replacement surgery.

So what: According to the early morning press release, ISIS-FXI, which inhibits Factor XI, a coagulation factor that plays a role in forming blood clots, produced a dose-dependent decrease in venous thrombotic events (VTE), as well as a reduced number of bleeding events compared to Lovenox. As noted by Isis, the highest dose (300 mg) produced a seven-fold lower incidence of VTEs than Lovenox. Furthermore, there were no observed differences in safety between ISIS-FXI and Lovenox. Isis announced its intentions to report its full data from the trial at an upcoming scientific meeting.

Now what: Chalk up yet another impressive study for Isis which is swinging for the fences with close to three dozen in-house and partnered therapies currently in its pipeline. Because Isis' pipeline is so diverse, and it has so many large-scale partners, its chances of hitting a home run are greatly increased. Early indications from ISIS-FXI demonstrate that it could be a very successful blood-thinning agent, and as Isis points out, it could represent another major licensing opportunity for the company which means more money upfront to fuel its ongoing research. Of the predominantly clinical-stage crowd (Isis has one FDA approved therapy) Isis is among my favorites due to its extensive pipeline and collaborative capacity, and I would suggest you add it to your watchlist.

Isis shares may have soared today, but they'll likely have a difficult time keeping pace with this top stock over the long run
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2968833, ~/Articles/ArticleHandler.aspx, 12/19/2014 7:28:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement